GlassScriptPhysician profile
Joel W Duncan
NPI 1871542779
$7,779.41
in general payments reported to CMS, 2019-2025
38 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $1,003 · 2021: $1,393 · 2022: $1,515 · 2023: $1,053 · 2024: $855 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.33 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,466.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $726.59 | 2019-2024 | Xarelto |
| Pfizer INC. | $631.37 | 2019-2023 | |
| Amgen INC. | $499.09 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $497.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.46 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $365.98 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $347.55 | 2021-2025 | Verquvo |
| Abbott Laboratories | $297.74 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Bayer Healthcare Pharmaceuticals INC. | $291.36 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $275.53 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $211.32 | 2020-2024 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $193.32 | 2019-2024 | Camzyos, Eliquis |
| Inari Medical, INC. | $124.82 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astellas Pharma US INC | $119.18 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $118.30 | 2019-2021 | |
| Bardy Diagnostics, INC. | $102.90 | 2019-2022 | |
| Biotronik INC. | $96.31 | 2019-2021 | |
| Daiichi Sankyo INC. | $93.93 | 2023-2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $93.22 | 2023-2024 | Inpefa |
| Medtronic, INC. | $87.63 | 2024-2025 | Intellis Adaptivestim |
| Baxter Healthcare | $81.94 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Abiomed | $78.29 | 2024-2025 | Impella |
| Kowa Pharmaceuticals America, INC. | $74.31 | 2020-2021 | |
| Vital Connect, INC | $65.11 | 2023-2024 | Vitalpatch Rtm |
| Cvrx, INC. | $64.06 | 2024-2025 | Barostim Neo System |
| Stryker Corporation | $57.75 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Regeneron Healthcare Solutions, INC. | $46.31 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $43.78 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $38.58 | 2022-2025 | Nexletol |
| Boston Scientific Corporation | $36.46 | 2019-2021 | |
| Scpharmaceuticals INC. | $30.30 | 2025 | |
| Noven Therapeutics, LLC | $21.27 | 2024 | Xelstrym |
| Intra-Sana Laboratories | $20.94 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Edwards Lifesciences Corporation | $20.72 | 2022 | |
| Akcea Therapeutics, INC. | $19.75 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.15 | 2019 | |
| Vifor Pharma, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.